Skip to main content

Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study



Patients with peripheral artery disease (PAD) are treated with preventive strategies to improve the cardiovascular risk. The incidence of cardiovascular events and mortality however remains high in PAD populations. We therefore aimed to better characterize PAD patients suffering from cardiovascular events and mortality in order to tailor preventive treatment.


Between 2018 and 2020, 246 PAD outpatients (17 newly diagnosed, 229 with known PAD) were prospectively enrolled in this observational cohort study. Patient data and blood samples were collected after inclusion, and the primary composite endpoint (myocardial infarction, elective coronary revascularization, ischemic stroke, acute limb ischemia, mortality) was evaluated after one year. Secondary outcomes included platelet reactivity, measured using the VerifyNow assay, and medication adherence, assessed using the Morisky Medication Adherence Scale-8 (MMAS-8). Logistic regression models were used to identify associations between characteristics and the occurrence of events.


The cohort comprised 207 patients with claudication and 39 with chronic limb threatening ischemia. Twenty-six (10.6%) patients suffered from an event during follow-up. Prior myocardial infarction (OR 3.3 [1.4–7.7]), prior ischemic stroke (OR 4.5 [1.8–10.9]), higher levels of creatinine (OR 5.2 [2.2–12.6]), lower levels of high-density lipoprotein (OR 4.2 [1.5–10.6]) and lower haemoglobin levels (OR 3.1 [1.3–7.1]) were associated with events. Patients with events had more often high on-treatment platelet reactivity (HTPR) on aspirin (OR 5.9 [1.4–25.1]) or clopidogrel (OR 4.3 [1–19.3]). High adherence to medication was associated with the occurrence of events (OR 4.1 [1–18]).


Patients suffering from cardiovascular events and mortality were characterized by prior cardiovascular events as compared to patients who did not experience any events. Antiplatelet therapy was not optimally protective despite high medication adherence, and HTPR was independently associated with the occurrence of events. More research is needed on alternative treatment strategies such as dual antiplatelet therapy or combinations with anticoagulant drugs.

Trial registration

The Medical Ethics Committee (METC) of the MUMC+ approved the study (NL63235.068.17) and the study was registered in the Netherlands Trial Register (NTR7250).


Peripheral artery disease (PAD) is a vascular disease characterized by atherosclerosis-driven narrowing of peripheral arteries. The prevalence of PAD worldwide in individuals aged twenty-five years and older was estimated at 236 million in 2015 [1]. Despite its high prevalence, PAD remains underdiagnosed as many patients are asymptomatic and thus not aware of the disease [2]. However, both asymptomatic and symptomatic PAD patients are at risk of atherothrombotic events such as myocardial infarction and ischemic stroke with incidences of 15% over a period of three years [3, 4]. Within the symptomatic patient population, intermittent claudication, a mild manifestation of PAD, can be distinguished from the more severe chronic limb threatening ischemia. Intermittent claudication is classified as Fontaine II with typical symptoms of muscle pain during walking. Chronic limb threatening ischemia is classified as Fontaine III with rest pain and Fontaine IV with ischemic ulcer formation [5, 6]. PAD patients with chronic limb threatening ischemia are at a higher risk of adverse cardiovascular events with high mortality rates as compared to patients with intermittent claudication [4]. Current preventive strategies for cardiovascular events and mortality in PAD patients are based on risk management in which lipid-lowering drugs, antihypertensive drugs and antiplatelet drugs are the main treatment modalities. Statins are most widely used to improve the lipid profile targeted at a low-density lipoprotein (LDL) value of 1.8 mmol/L for PAD patients of 70 years or younger and a value of 2.5 mmol/L for PAD patients above 70 years [7]. By effectively lowering LDL levels, the incidence of cardiovascular events can be reduced significantly [8]. Addition of antihypertensive drugs to overcome hypertension as well as the use of antiplatelet drugs to effectively inhibit platelet activation reduces the incidence of cardiovascular events even further. Aspirin and clopidogrel are the antiplatelet drugs most often used as first-line treatment depending on national guidelines [5]. Although the CAPRIE-study demonstrated that clopidogrel was more effective than aspirin in reducing the combined risk of ischemic stroke, myocardial infarction, and cardiovascular death, this is no preferential treatment strategy [9]. Despite the established efficacy of antiplatelet regimes with regard to the reduction of cardiovascular events, high on-treatment platelet reactivity (HTPR) for both aspirin and clopidogrel may still occur and interfere with atheroprotective effects. HTPR is referred to as the failure of the antiplatelet agent to inhibit the target of its action [10, 11]. Aspirin HTPR prevalence is estimated at 17–26% in PAD populations [12,13,14] while clopidogrel HTPR appears to be more common with a prevalence up to 54% [12, 14,15,16]. The incidence of cardiovascular events in PAD populations remains high despite current treatment strategies [3]. Therefore, the aim of this observational cohort study was to better characterize PAD patients at risk of cardiovascular events and mortality in order to find targets for improved management.


Study design

Between May 2018 and May 2020, patients visiting the outpatient clinic of the department of Vascular Surgery of the Maastricht University Medical Center (MUMC+) were screened for PAD. Patients were eligible to participate in the study when the PAD was objectively diagnosed with an ankle-brachial index (ABI) of 0.9 or below. Fontaine II (intermittent claudication) and Fontaine III (chronic limb threatening ischemia) patients were selected and patients with Fontaine IV were excluded because of expected increased inflammatory parameters associated with ulcer formation. Further exclusion criteria were active malignancy, chronic inflammatory disease, coagulation disorders, pregnancy, age below 18, and the use of anticoagulant therapy. All eligible patients that were willing to participate were included after written informed consent was obtained. The Medical Ethics Committee (METC) of the MUMC+ approved the study (NL63235.068.17) and the study was registered in the Netherlands Trial Register (NTR7250;

Blood collection and sample storage

Venous blood was drawn from the patients immediately after informed consent was signed. Blood drawing took place in a resting state and blood was collected by antecubital venipuncture with 21-gauge needles and 3.2% (w/v) citrated Vacutainer glass tubes, EDTA Vacutainer glass tubes and VACUETTE 9NC Coagulation 3.2% (w/v) Sodium Nitrate glass tubes. After blood drawing, the EDTA tubes and the citrate tubes were directly processed using the standard platelet-poor plasma centrifugation protocol used at our laboratory (4000 x g for 5 minutes followed by 11,000 x g for 10 minutes). Thereafter samples were, within two hours after blood drawing, frozen and stored at − 80° Celsius for further analysis. The VACUETTE 9NC tubes were immediately used to perform the VerifyNow assays for aspirin and clopidogrel.

Data collection and measurements

Age, sex and date of PAD diagnosis of each patient were registered upon inclusion. The medical history of each patient including prior cardiovascular events such as myocardial infarction, ischemic stroke and PAD revascularization was collected from patient records. Each patient provided an updated medication list from which the use of lipid-lowering drugs, antihypertensive drugs and antiplatelet drugs were collected. The intensity of lipid-lowering strategies was categorized as high, medium and low intensity according to the ACC/AHA guideline [17]. Current smoking status, diabetes mellitus type 2 (DM2) and body mass index (BMI) were recorded. Patients were classified based on their symptoms upon inclusion using the Fontaine classification, and were then grouped as having intermittent claudication (Fontaine II) or chronic limb threatening ischemia (Fontaine III). The ABI at the time of diagnosis was measured and grouped by ratio as greater than 1.3 (incompressible), between 0.91 and 1.3, between 0.7 and 0.9, between 0.4 and 0.69 and below 0.4.

A complete blood cell count was performed at baseline and included levels of haemoglobin, haematocrit, thrombocytes and leukocytes with respective subpopulations. Platelet reactivity was assessed using the VerifyNow Aspi assay for Aspirin and VerifyNow P2Y12 assay for Clopidogrel (Accumetrics, San Diego, CA, USA). Blood collected in the VACUETTE 9NC tube was used in the optical detection system using a specific cartridge. The cut-off value for aspirin and clopidogrel HTPR was based on the most recent consensus document on the definition of on-treatment platelet reactivity, and was set at Aspirin Reaction Units (ARU) > 550 for aspirin [18] and P2Y12 Reaction Units (PRU) > 208 for clopidogrel [11]. Laboratory results that were collected from recent blood drawing included kidney function (creatinine, estimated glomerular filtration rate-Chronic Kidney Disease Epidemiology Collaboration (eGFR (CKD-EPI))), lipid profile (cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides) and haemoglobin A1c levels (HbA1c). The KDIGO guideline was used to classify the kidney function, and the stage of chronic kidney disease in each patient when appropriate [19].

Medication adherence was assessed by the licensed Morisky Medication Adherence Scale-8 (MMAS-8), which was developed by Morisky et al. The MMAS-8 is a validated assessment tool verified by numerous studies, consisting of eight questions to assess medication adherence [20,21,22]. Patients that were completely adherent scored a maximum score of 8, whereas the lowest possible adherence was scored 0. Each point decrease marked lower adherence to the medical treatment. According to MMAS-8 user guidelines the adherence was categorized as high (8 points), medium (7 or 6 points) and low (5 points or below).


The primary outcome consisted of a composite endpoint comprising myocardial infarction, ischemic stroke, acute limb ischemia, elective percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) and all-cause mortality during the one-year follow-up. The outcome was assessed at 3, 6 and 12 months and was verified by telephone calls to the patient combined with hospital records. Patients who reached the composite endpoint were grouped as the “PAD event group” while patients who did not reach the composite endpoint were grouped as the “PAD no event group”. The secondary outcomes were platelet reactivity, HTPR and medication adherence.

Statistical analysis

Baseline characteristics were collected for all patients and presented for patients with and without events during follow-up. Differences between both groups were analyzed using the chi-square test for dichotomous and categorical variables. For continuous variables, differences were analyzed using the parametric two-samples t-test or the non-parametric Mann-Whitney U test, as appropriate. Youden’s index was used, when appropriate, to determine optimal cut-off values for continuous variables. Univariable logistic regression models were used to test the associations of characteristics with the occurrence of events, reported as odds ratios with respective 95% confidence intervals (OR [95% CI]). Characteristics with an association with the occurrence of events (p < 0.05) in the univariable analysis were then used in multivariable models with backward stepwise logistic regression analysis for the occurrence of events, reported as odds ratios with respective 95% confidence intervals. Statistical significance was reached when p < 0.05. All analyses were performed using SPSS (IBM SPSS Statistics for Macintosh, Version 27.0. Armonk, NY: IBM Corp). All figures were created using GraphPad Prism (GraphPad Prism version 9 for Mac OS X, GraphPad Software, San Diego, California USA,


Patient characteristics

The cohort comprised 246 patients and baseline characteristics of the entire cohort as well as the distribution of patients with and without events are shown in Table 1. All patients had been diagnosed with PAD at a median of 33 (8–101) months prior to inclusion, while in 17 (6.9%) patients the diagnosis was established at the time of inclusion. Upon inclusion, most patients had intermittent claudication (207 (84.1%)) and 39 (15.9%) had chronic limb threatening ischemia. The cohort consisted of 141 (57.3%) male patients and the mean age was 68.7 ± 9.2 years. Most patients (109 (44.3%)) had an ABI between 0.7 and 0.9, while 99 (40.2%) and 21 (8.5%) patients had an ABI between 0.4 and 0.69 or below 0.4, respectively. The remaining 17 (6.9%) patients had incompressible arteries. Patient history revealed that 151 (61.4%) patients had previously undergone a peripheral revascularization procedure. Moreover, 72 (29.3%) patients had a prior myocardial infarction and 37 (15%) had a prior ischemic stroke. DM2 was present in 67 (27.2%) patients and the mean BMI was 26.4 ± 4.41 kg/m2. Of all patients, 229 (93.1%) had a history of smoking and 94 (38.2%) were current smokers with a median of 29 (15–40) pack years upon inclusion. A normal kidney function (G1) was observed in 41 (16.7%) patients, a mildly decreased kidney function (G2) in 138 (56.1%) patients, a mildly to moderately decreased kidney function (G3a) in 41 (16.7%) patients, a moderately to severe decreased kidney function (G3b) in 19 (7.7%) patients, a severely decreased kidney function (G4) in 6 (2.3%) patients and kidney failure (G5) in 1 (0.4%) patient.

Table 1 Baseline characteristics

Composite endpoint

All patients were followed for one year in which 26 (10.6%) patients reached the composite endpoint. Ten (38.5%) myocardial infarctions, four (15.4%) elective coronary revascularizations, five (19.2%) ischemic strokes and seven (26.9%) deaths were recorded. No differences were observed between patients with and without events regarding smoking status, DM2 and BMI. Both prior myocardial infarction (OR 3.3 [1.4–7.7]) and prior ischemic stroke (OR 4.5 [1.8–10.9]) were associated with the occurrence of events (Fig. 1). Also, decreased kidney function (plasma creatinine level > 111 μmol/L, OR 5.2 [2.2–12.6]) and plasma haemoglobin levels < 8.1 mmol/L (OR 3.1 [1.3–7.1]) were associated with the occurrence of events. Leukocyte and thrombocyte count were not associated.

Fig. 1
figure 1

Univariable logistic regression analysis of characteristics associated with the occurrence of cardiovascular events and mortality, with corresponding odds ratios and 95% confidence intervals. HTPR = high on-treatment platelet reactivity, HDL = high-density lipoprotein, SD = standard deviation, IQR = interquartile range

Evaluation of medication strategies

All patients were treated according to current guidelines [5] which included the use of antihypertensive drugs, lipid-lowering drugs and antiplatelet drugs. The prescription of antihypertensive drugs (73.1% vs 72.7%, p = 0.834), lipid-lowering drugs (88.5% vs 90%, p = 0.396) and antiplatelet drugs (100% vs 100%, p = 1.000) did not differ between patients with and without events. Lipid-lowering strategies were prescribed in different intensities. A total of 71 (32.6%) patients were on high intensity lipid-lowering therapy without differences between patients with and without events (31.8% vs 32.7%, p = 0.937). Moderate and low intensity therapy had been applied in 138 (63.3%) and 9 (4.1%) patients, but also in these groups no differences were observed between patients with and without events (63.6% vs 63.3%, p = 0.973 and 4.5% vs 4.1%, p = 0.917 respectively). The effectiveness of the lipid-lowering therapies was assessed using the cholesterol profile, showing similar mean LDL levels of 2.44 ± 1.07 mmol/L between patients with events and those without (2.31 ± 1.14 mmol/L vs 2.45 ± 1.06 mmol/L, p = 0.542). In 58.5% of patients above 70 years old the LDL target level of 2.5 mmol/L was reached (2.49 ± 1.18 mmol/L), while the target level of 1.8 mmol/L was not reached in 95 (72%) patients 70 years or younger (2.39 ± 0.97 mmol/L). HDL levels were significantly lower in patients who experienced an event during follow-up (OR 4.2 [1.5–10.6]). The use of antiplatelet agents was evenly distributed in the cohort with 130 (52.8%) patients on aspirin, 127 (51.6%) on clopidogrel. Additionally, 11 (4.5%) patients were on dual antiplatelet therapy. During the conduct of this study, there was a transitioning of aspirin to clopidogrel as first choice antiplatelet agent in the hospital where patients were recruited. Therefore, some patients were using aspirin upon inclusion, while others were using clopidogrel. The median ARU on aspirin was 435 (402–482) and 12 (8.5%) patients had HTPR. The ARU in patients with events during follow-up was significantly higher compared to those without events (521 (452–554) vs 428 (401–478), p = 0.011) and HTPR was associated with the occurrence of events (OR 5.9 [1.4–25.1]). PRU in patients on clopidogrel were 100 (46–155) for the whole cohort and significantly higher in patients with events (144 (102–190) vs 96 (43–144), p = 0.019) (Fig. 2). HTPR on clopidogrel was observed in 8 (5.8%) patients and was associated with events (OR 4.3 [1–19.3]). In the multivariable analysis the adjusted OR for antiplatelet therapy was 5.2 [1.5–18.5] (Fig. 3).

Fig. 2
figure 2

Platelet reactivity measured by the use of the VerifyNow assay in Aspirin Reactions Units (ARU) for aspirin users and P2Y12 Reaction Units (PRU) for clopidogrel users. Dotted lines represent HTPR which is an ARU > 550 for aspirin and a PRU > 208 for clopidogrel

Fig. 3
figure 3

Multivariable logistic regression of characteristics associated with the occurrence of cardiovascular events and mortality, with corresponding odds ratios and 95% confidence intervals. HTPR = high on-treatment platelet reactivity, HDL = high-density lipoprotein, SD = standard deviation, IQR = interquartile range

High medication adherence was observed in 188 (76.4%) patients and was positively associated with the occurrence of events (OR 4.1 [1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18]). Medium adherence was observed in 46 (18.7%) patients and low adherence in 12 (4.9%) patients, both were not associated with the occurrence of events.


In this prospective observational cohort study, we characterized PAD patients with enhanced risk for cardiovascular events and mortality with the aim to find targets for improved management. Most patients in our cohort had prevalent PAD with a chronic state of atherosclerosis with years of plaque build-up and involvement of multiple vascular beds with associated decrease in renal function in conjunction with lower haemoglobin levels. Patients with such polyvascular disease are at increased risk for cardiovascular events with worsening prognosis when more vascular beds are affected [23]. In almost half of the patients in the cohort this polyvascular diseased state was present.

All patients in our cohort were treated with lipid-lowering agents, antiplatelet therapy and antihypertensive drugs. Interestingly, the medication prescribed did not appear to be sufficiently protective for PAD patients experiencing cardiovascular events and mortality, despite adequate adherence to the medication. Suboptimal target LDL levels were observed. The intensity of the lipid-lowering strategies prescribed was medium to high according to the ACC/AHA guidelines [7]. The LDL target level of 2.5 mmol/L was indeed reached in more than half of all patients older than 70 years. On the other hand, average LDL levels in patients of 70 years or younger were similar to the older patient group, while in these patients LDL levels of 1.8 mmol/L or lower are recommended. Especially in these younger patients the lipid-lowering regimen should ideally be intensified, which will likely result in a reduced incidence of cardiovascular events as the association between increased LDL levels and cardiovascular risk is well established [24]. Potentially, LDL target values of 1.8 and 2.5 mmol/L could even be lowered further as a recent study showed that lower concentrations of LDL may even better prevent cardiovascular events [25]. Also lower HDL levels were seen in patients that suffered from an event during follow-up, which indirectly supports the known atheroprotective effects of HDL including counteracting inflammation [26] and oxidative stress [27]. Several studies have found an association between lower HDL levels and cardiovascular risk in patients with coronary artery disease [28, 29] and low concentrations of HDL as one of the strongest lipoprotein risk factors for PAD [30, 31].

The VerifyNow assay was used to measure platelet reactivity while on aspirin or clopidogrel (or both). The residual platelet reactivity in patients on aspirin or on clopidogrel was significantly higher in patients experiencing events, indicating that platelets are less efficiently inhibited. Lack of medication adherence could have caused residual platelet reactivity. However, this did not seem to be the case as the results of the adherence score revealed that highly adherent patients were in the majority in the event group, which could be the result of increased awareness in this patient group as these patients more often experienced prior myocardial infarctions and ischemic strokes. Therefore, assuming that the adherence assessment is reliable, the current antithrombotic regime appears to be insufficient for adequate cardiovascular protection in these high-risk patients. Published studies show conflicting results regarding the association of HTPR with cardiovascular outcome. Two studies investigating clopidogrel HTPR found a significant association with cardiovascular events while two other studies did not [12, 14,15,16]. These studies used the same cut-off values for HTPR and follow-up duration was also similar. The contradicting results may however be explained by the lack of power. One study found a non-significant trend between clopidogrel HTPR and cardiovascular events [12], while the other study found a non-significantly increased hazard ratio in patients with HTPR [14]. In all four studies the prevalence of clopidogrel HTPR was higher as compared to the HTPR prevalence in our study, which could be explained by differences in medication adherence. We were not able to confirm this as other studies did not report on adherence. The strength of the risk association of HTPR that we found for both aspirin and clopidogrel suggests that optimization of antiplatelet therapy is an important management target for improvement. For aspirin, there is no known mechanism for biochemical resistance, but high platelet turnover could be a reason for residual platelet hyperreactivity [32]. In patients taking clopidogrel the HTPR could be explained by genetic polymorphisms in platelet receptor P2Y12 [33, 34] or polymorphisms of the CYP2C9 and CYP2C19 genes [35, 36]. Recent studies in patients with coronary artery disease investigated pharmacogenomics based on CYP2C19 gene variations to optimize therapy [37, 38]. Moreover, a meta-analysis concluded that the use of ticagrelor or prasugrel appeared more effective than clopidogrel in reducing the cardiovascular risk in patients with CYP2C19 gene variants [39]. Similar studies have yet to be performed in patients with PAD. The association between P2Y12 polymorphisms and the risk for cerebrovascular events in PAD patients has been established in the past [40]. Indeed, recent studies suggest that a twice-daily dosing of aspirin could improve its pharmacological efficacy. In patients with essential thrombocythemia a once-daily dose of aspirin as antithrombotic regime appeared inadequate in reducing platelet activation, while a dosing interval of 12 hours increased the antiplatelet response to aspirin [41, 42]. For clopidogrel, studies with increased dosing to compensate for the low inhibitory efficacy have been performed in the past [43], assuming “resistance” to be in part explained by too low concentrations of active clopidogrel at the platelet surface [44, 45]. However, apart from the use of loading doses in patients undergoing percutaneous coronary interventions, such regimens were never introduced in clinical practice in patients with PAD [46]. Dual antiplatelet therapy (DAPT) has been studied in the large CHARISMA trial [47]. Except for exceptionally thrombogenic conditions DAPT has not been introduced for long-term treatment of patients with PAD because of increased bleeding risk as compared to single antiplatelet therapy. Guidelines only recommend DAPT for a short period of time following percutaneous interventions and stenting in PAD. Several studies demonstrated that fibrinogen [48, 49] and d-dimer [50] levels were increased in high-risk PAD patients indicating an underlying hypercoagulable state. Anticoagulant treatment may counteract this prothrombotic state in PAD patients which is characterized by increased clot formation [51]. The COMPASS-trial has shown that dual pathway inhibition with aspirin and a low dose rivaroxaban reduced the incidence of cardiovascular events in high-risk PAD patients [52], suggesting that a reasonably low level of anticoagulation on top of antiplatelet therapy provides additional benefit. In spite of its demonstrated cost-effectiveness in at least a subset of PAD patients [53], the use of dual pathway inhibition in practice is still hindered by low uptake due to concerns about the number of pills per day in combination with an increased risk of major bleeding, even though fatal or critical organ bleeding events remained limited [52].


The use of the VerifyNow assay to identify HTPR may be perceived as a possible limitation of this study. Several studies have however shown that this assay correlates well with the “gold standard” of light transmission aggregometry for both aspirin [54] and clopidogrel [55]. The recorded rates of HTPR within our study population were lower than rates reported by most other studies [12, 14,15,16], this can however be explained by the overall high medication adherence rate that we recorded. The positive association that was found between high medication adherence and higher risk for cardiovascular events in the multivariable analysis may be confounded as this risk is likely to be primarily attributed to the higher rate of comorbidities and prior cardiovascular events leading to the increased motivation to be adherent to medication in these patients. Finally, due to sample size limitations, there is a lack of precision surrounding the estimates which demonstrates that there is still uncertainty about the actual effect size and that further information is needed.


In our single-center cohort of PAD patients, current treatment strategies appeared to be insufficient for the reduction of cardiovascular risk. Lipid-lowering strategies should be intensified to further reduce LDL levels and improve the lipid profile. Antiplatelet agents were found to be inadequate despite high medication adherence, as platelet reactivity was insufficiently decreased in patients experiencing cardiovascular events. More research is needed on alternative treatment strategies such as dual antiplatelet therapy or combinations with anticoagulant drugs.

Availability of data and materials

Data will be available upon reasonable request by B. Kremers.



Ankle-brachial index


Aspirin reaction units


Body mass index


Coronary artery bypass grafting


Diabetes mellitus type 2


Estimated glomerular filtration rate-Chronic Kidney Disease Epidemiology Collaboration


Haemoglobin A1c


High-density lipoprotein


High on-treatment platelet reactivity


Low-density protein


Medical Ethics Committee


Morisky Medication Adherence Scale-8


Maastricht University Medical Center


Odds ratio


P2Y12 reaction units


Peripheral artery disease


Percutaneous intervention


  1. Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health Elsevier BV. 2019;7:e1020–30.

    Article  Google Scholar 

  2. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol Oxford University Press (OUP). 1991;20:384–92.

    CAS  Google Scholar 

  3. Alberts MJ, Bhatt DL, Mas J-L, Ohman EM, Hirsch AT, Röther J, et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for continued health registry. Eur Heart J. 2009;30:2318–26.

    Article  Google Scholar 

  4. Sartipy F, Sigvant B, Lundin F, Wahlberg E. Ten year mortality in different peripheral arterial disease stages: a population based observational study on outcome. Eur J Vasc Endovasc Surg. 2018;55:529–36.

    Article  Google Scholar 

  5. Aboyans V, Ricco J-B, Bartelink M-LEL, Björck M, Brodmann M, Cohnert T, et al. ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2017;2018(39):763–816.

    Google Scholar 

  6. Fontaine R, Kim M, Kieny R. Surgical treatment of peripheral circulation disorders. Helv Chir Acta. 1954;21:499–533.

    CAS  Google Scholar 

  7. Stone NJ, Robinson JG, Lichtenstein AH, Goff DC Jr, Lloyd-Jones DM, Smith SC Jr, et al. Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med American College of Physicians. 2014;160:339–43.

    Google Scholar 

  8. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–61.

    Article  CAS  Google Scholar 

  9. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39.

  10. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. Elsevier BV. 2010;56:919–33.

    Article  CAS  Google Scholar 

  11. Tantry US, Bonello L, Aradi D, Price MJ, Jeong Y-H, Angiolillo DJ, et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol Elsevier BV. 2013;62:2261–73.

    Article  CAS  Google Scholar 

  12. Yeo K-K, Armstrong EJ, López JE, Chen DC, Westin GG, Li C-S, et al. Aspirin and clopidogrel high on-treatment platelet reactivity and genetic predictors in peripheral arterial disease. Catheter Cardiovasc Interv. 2018;91:1308–17.

    Article  Google Scholar 

  13. Pasala T, Hoo JS, Lockhart MK, Waheed R, Sengodan P, Alexander J, et al. Aspirin resistance predicts adverse cardiovascular events in patients with symptomatic peripheral artery disease. Tex heart Inst J. 2016;43:482–7.

    Article  Google Scholar 

  14. Armstrong EJ, Anderson DR, Yeo K-K, Singh GD, Bang H, Amsterdam EA, et al. Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg Elsevier BV. 2015;62:157–165.e1.

    Article  Google Scholar 

  15. Pastromas G, Spiliopoulos S, Katsanos K, Diamantopoulos A, Kitrou P, Karnabatidis D, et al. Clopidogrel responsiveness in patients undergoing peripheral angioplasty. Cardiovasc Radiol Springer Science and Business Media LLC. 2013;36:1493–9.

    Google Scholar 

  16. Spiliopoulos S, Kassimis G, Hatzidakis A, Krokidis M. High on-treatment platelet reactivity in peripheral endovascular procedures. Cardiovasc Radiol. Springer Science and Business Media LLC. 2014;37:559–71.

    Google Scholar 

  17. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014;63:2889–934.

    Article  Google Scholar 

  18. Lee P-Y, Chen W-H, Ng W, Cheng X, Kwok JY-Y, Tse H-F, et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med Elsevier BV. 2005;118:723–7.

    Article  CAS  Google Scholar 

  19. Disease K. Improving global outcomes (KDIGO) blood pressure work group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int Elsevier BV. 2021;99:S1–87.

    Article  Google Scholar 

  20. Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10:348–54.

    Article  Google Scholar 

  21. Krousel-Wood M, Islam T, Webber LS, Re RN, Morisky DE, Muntner P. New medication adherence scale versus pharmacy fill rates in seniors with hypertension. Am J Manag Care. 2009;15:59–66.

    Google Scholar 

  22. Morisky DE, DiMatteo MR. Improving the measurement of self-reported medication nonadherence: response to authors. J Clin Epidemiol. 2011;64:255–7. discussion 258-63

  23. Subherwal S, Bhatt DL, Li S, Wang TY, Thomas L, Alexander KP, et al. Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Qual Outcomes Ovid Technologies (Wolters Kluwer Health). 2012;5:541–9.

    Article  Google Scholar 

  24. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. Oxford University Press (OUP). 2017;38:2459–72.

    Article  CAS  Google Scholar 

  25. Sabatine MS, Wiviott SD, Im K, Murphy SA, Giugliano RP. Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels. JAMA Cardiol. American Medical Association (AMA); 2018; Available from:

  26. Barter PJ, Nicholls S, Rye K-A, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. Circ Res Ovid Technologies (Wolters Kluwer Health). 2004;95:764–72.

    CAS  Google Scholar 

  27. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol Ovid Technologies (Wolters Kluwer Health). 2010;21:312–8.

    Article  CAS  Google Scholar 

  28. Giugliano RP, Pedersen TR, Park J-G, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. Elsevier BV. 2017;390:1962–71.

    Article  CAS  Google Scholar 

  29. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham heart study. Arteriosclerosis. Ovid Technologies (Wolters Kluwer Health). 1988;8:737–41.

    Article  CAS  Google Scholar 

  30. Murabito JM, Evans JC, Nieto K, Larson MG, Levy D, Wilson PW, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham offspring study. Am Heart J Elsevier BV. 2002;143:961–5.

    Article  Google Scholar 

  31. Newman AB, Siscovick DS, Manolio TA, Polak J, Fried LP, Borhani NO, et al. Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Cardiovascular heart study (CHS) Collaborative Research Group. Circulation. Ovid Technologies (Wolters Kluwer Health). 1993;88:837–45.

    Article  CAS  Google Scholar 

  32. Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost. 2008;99:930–5.

    Article  CAS  Google Scholar 

  33. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny J-L, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation Ovid Technologies (Wolters Kluwer Health). 2003;108:989–95.

    Article  CAS  Google Scholar 

  34. Lee S-J, Jung I-S, Jung E-J, Choi J-Y, Yeo C-W, Cho D-Y, et al. Identification of P2Y12 single-nucleotide polymorphisms and their influences on the variation in ADP-induced platelet aggregation. Thromb Res Elsevier BV. 2011;127:220–7.

    Article  CAS  Google Scholar 

  35. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5:2429–36.

    Article  CAS  Google Scholar 

  36. Hulot J-S, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244–7.

    Article  CAS  Google Scholar 

  37. Claassens DM, Vos GJ, Bergmeijer TO, Hermanides RS, Van’t Hof AW, Van Der Harst P, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N Engl J Med Massachusetts Medical Society. 2019;381:1621–31.

    Article  CAS  Google Scholar 

  38. Pereira NL, Farkouh ME, So D, Lennon R, Geller N, Mathew V, et al. Effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. JAMA. 2020;324:761–71.

    Article  CAS  Google Scholar 

  39. Pereira NL, Rihal C, Lennon R, Marcus G, Shrivastava S, Bell MR, et al. Effect of CYP2C19 genotype on ischemic outcomes during oral p2y12 inhibitor therapy: a meta-analysis. JACC Cardiovasc Interv. 2021;14:739–50.

  40. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke Ovid Technologies (Wolters Kluwer Health). 2005;36:1394–9.

    Article  CAS  Google Scholar 

  41. Rocca B, Tosetto A, Betti S, Soldati D, Petrucci G, Rossi E, et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood American Society of Hematology. 2020;136:171–82.

    Article  Google Scholar 

  42. Larsen ML, Pedersen OH, Hvas AM, Niekerk PB, Bønløkke S, Kristensen SD, et al. Once- versus twice-daily aspirin treatment in patients with essential thrombocytosis. Platelets. Informa UK Limited. 2019;30:322–8.

    Article  CAS  Google Scholar 

  43. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix response in coronary intervention) trial. JACC Cardiovasc Interv. Elsevier BV. 2008;1:612–9.

    Article  Google Scholar 

  44. Louca JI, Mina GS, Habib BW, Sadek SE. The effect of doubling the dose of clopidogrel on platelet aggregation in patients with clopidogrel resistance. Egypt Heart J Springer Science and Business Media LLC. 2014;66:259–62.

    Article  Google Scholar 

  45. Aleil B, Jacquemin L, De Poli F, Zaehringer M, Collet J-P, Montalescot G, et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (vasodilator-stimulated Phosphoprotein-02) randomized study. JACC Cardiovasc Interv Elsevier BV. 2008;1:631–8.

    Article  Google Scholar 

  46. Siller-Matula JM, Huber K, Christ G, Schrör K, Kubica J, Herkner H, et al. Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Heart BMJ. 2011;97:98–105.

    Article  CAS  Google Scholar 

  47. Bhatt DL, Topol EJ, Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J. Elsevier BV. 2004;148:263–8.

    Article  CAS  Google Scholar 

  48. Altes P, Perez P, Esteban C, Sánchez Muñoz-Torrero JF, Aguilar E, García-Díaz AM, et al. Raised fibrinogen levels and outcome in outpatients with peripheral artery disease. Angiology SAGE Publications. 2018;69:507–12.

    Article  CAS  Google Scholar 

  49. Doweik L, Maca T, Schillinger M, Budinsky A, Sabeti S, Minar E. Fibrinogen predicts mortality in high risk patients with peripheral artery disease. Eur J Vasc Endovasc Surg Elsevier BV. 2003;26:381–6.

    Article  CAS  Google Scholar 

  50. Kleinegris M-CF, ten Cate H, ten Cate-Hoek AJ. D-dimer as a marker for cardiovascular and arterial thrombotic events in patients with peripheral arterial disease. A systematic review. Thromb Haemost. Georg Thieme Verlag KG. 2013;110:233–43.

    Article  CAS  Google Scholar 

  51. Kleinegris M-CF, Konings J, Daemen JW, Henskens Y, de Laat B, Spronk HMH, et al. Increased clot formation in the absence of increased thrombin generation in patients with peripheral arterial disease: a case-control study. Front Cardiovasc Med Frontiers Media SA. 2017;4:23.

    Article  Google Scholar 

  52. Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet Elsevier BV. 2018;391:219–29.

    Article  CAS  Google Scholar 

  53. Petersohn S, Pouwels X, Ramaekers B, Ten Cate-Hoek A, Joore M. Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study. Eur J Prev Cardiol Oxford University Press (OUP). 2020;27:1354–65.

    Article  Google Scholar 

  54. Paniccia R, Antonucci E, Gori AM, Marcucci R, Poli S, Romano E, et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am J Clin Pathol Oxford University Press (OUP);. 2007;128:143–9.

    Article  CAS  Google Scholar 

  55. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost Wiley. 2007;5:1839–47.

    Article  CAS  Google Scholar 

Download references


We thank Marieke Pavlicic for blood drawing and inclusion of patients. We also thank Stella Schreurs and the vascular surgery residents of the MUMC+ for the recruitment of patients.

Author information

Authors and Affiliations



BK, JD, HC, HS, BM, AtC-H contributed to the conception and design of the study. JD and BM included patients. BK acquired data and BK and AtC-H analyzed and interpreted the data. BK drafted the manuscript, JD, HC, HS, BM and AtC-H performed critical revision of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to B. M. M. Kremers.

Ethics declarations

Ethics approval and consent to participate

The Medical Ethics Committee (METC) of the MUMC+ approved the study, and each patient provided written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kremers, B.M.M., Daemen, J.H.C., ten Cate, H. et al. Inadequate response to antiplatelet therapy in patients with peripheral artery disease: a prospective cohort study. Thrombosis J 21, 5 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Atherosclerosis
  • Atherothrombosis
  • Peripheral artery disease
  • Cardiovascular risk
  • Antiplatelet therapy
  • High on-treatment platelet reactivity